About Alentis Therapeutics
Alentis Therapeutics is a company based in Basel (Switzerland) founded in 2019 by Thomas Baumert. Alentis Therapeutics has raised $365.66 million across 4 funding rounds from investors including Schroders, Orbimed and Bpifrance. Alentis Therapeutics offers products and services including ADC ALE.P02 and Lixudebart. Alentis Therapeutics operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
- Headquarter Basel, Switzerland
- Founders Thomas Baumert
- Stage Unicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alentis Therapeutics Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$365.66 M (USD)
in 4 rounds
-
Latest Funding Round
$181.4 M (USD), Series D
Nov 12, 2024
-
Investors
Schroders
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alentis Therapeutics
Alentis Therapeutics offers a comprehensive portfolio of products and services, including ADC ALE.P02 and Lixudebart.
Antibody-drug conjugate targeting squamous cancers for selective tumor cell killing.
Monoclonal antibody designed to reverse organ fibrosis through Claudin-1 targeting.
People of Alentis Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Alentis Therapeutics
Alentis Therapeutics has successfully raised a total of $365.66M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $181.4 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alentis Therapeutics
Alentis Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Schroders, Orbimed and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Jeito Capital is focused on financing medical innovation globally.
|
Locked | Locked | Locked |
Investor details for Alentis Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alentis Therapeutics
Investment portfolio details for Alentis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alentis Therapeutics
Detailed financials for Alentis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alentis Therapeutics Comparisons
Peer comparison for Alentis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alentis Therapeutics
Alentis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
Detailed competitors of Alentis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alentis Therapeutics
Complete news archive for Alentis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alentis Therapeutics
Alentis Therapeutics was founded in 2019.
Alentis Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Roberto Iacone is the current CEO of Alentis Therapeutics.
Alentis Therapeutics is a funded company, having raised a total of $365.66M across 4 funding rounds to date.
Alentis Therapeutics was founded in 2019 in Basel, Switzerland. Focus is placed on developing treatments for fibrosis, cirrhosis, and liver cancer within the biotechnology sector. A gene expression platform supports the advancement of monoclonal antibodies targeting the CLDN1 protein. These are investigated for advanced liver fibrosis, kidney fibrosis, hepatocellular carcinoma, and cholangiocarcinoma. Drug candidates in the pipeline include ALE-F02 and ALE-C04.
Alentis Therapeutics's top competitors include argenx, Zai Lab and Kodiak Sciences.
Alentis Therapeutics offers ADC ALE.P02 and Lixudebart.
Alentis Therapeutics has 14 investors. Key investors include Schroders, Orbimed, Bpifrance, RA Capital, and Novo Holdings.
The valuation of Alentis Therapeutics is $2B as of Jun 2021.